JADE BIOSCIENCES INC (JBIO)
Health Care · NASDAQ
A clinical-stage biopharmaceutical company developing novel monoclonal antibodies targeting autoimmune diseases, with lead candidate JADE101 for IgA nephropathy.
What JADE BIOSCIENCES INC does
Jade Biosciences is a clinical-stage biopharmaceutical company developing novel biologic therapies for autoimmune diseases. The company focuses on discovering and efficiently developing monoclonal antibodies that target emerging pathways with potential for improved dosing convenience, safety profiles, and clinical activity compared to existing treatments. Its pipeline includes JADE101 (anti-APRIL), JADE201 (anti-BAFF-R), and JADE301, with lead candidate JADE101 in Phase 1 development for IgA nephropathy.
Themes: []
Fundamentals
- Price$22.48 as of 2026-07-09 close
- Market cap$1.4B as of 2026-07-10
- 1-year return+115.0% as of 2026-07-09 close
- ROE-51.3% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta1.41 as of 2026-07-10
Key risks (from latest filing)
[]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.